Cargando…

Angiotensin II Type 1 Receptor Blockers Inhibit KAT II Activity in the Brain—Its Possible Clinical Applications

Angiotensin II receptor blockers (ARBs) are one of the most frequently recommended antihypertensive drugs. Apart from their activity towards the circulatory system, ARBs also penetrate the blood-brain barrier and display neuroprotective effects. Kynurenic acid (KYNA) is an endogenous metabolite of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zakrocka, Izabela, Targowska-Duda, Katarzyna M., Wnorowski, Artur, Kocki, Tomasz, Jóźwiak, Krzysztof, Turski, Waldemar A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602025/ https://www.ncbi.nlm.nih.gov/pubmed/28733707 http://dx.doi.org/10.1007/s12640-017-9781-2

Ejemplares similares

Influence of Cyclooxygenase-2 Inhibitors on Kynurenic Acid Production in Rat Brain in Vitro
por: Zakrocka, Izabela, et al.
Publicado: (2018)

Carlina oxide inhibits the interaction of SARS-CoV-2 S glycoprotein with angiotensin-converting enzyme 2
por: Wnorowska, Sylwia, et al.
Publicado: (2022)

Kynurenic Acid Protects against Thioacetamide-Induced Liver Injury in Rats
por: Marciniak, Sebastian, et al.
Publicado: (2018)

Kynurenic acid and cancer: facts and controversies
por: Walczak, Katarzyna, et al.
Publicado: (2019)

AhR and IDO1 in pathogenesis of Covid-19 and the “Systemic AhR Activation Syndrome:” a translational review and therapeutic perspectives
por: Turski, Waldemar A., et al.
Publicado: (2020)

Effects of Fenofibrate and Gemfibrozil on Kynurenic Acid Production in Rat Kidneys In Vitro: Old Drugs, New Properties
por: Zakrocka, Izabela, et al.
Publicado: (2023)

Effect of an angiotensin II type 1 receptor blocker on caveolin-1 expression in prostate cancer cells
por: Piastowska-Ciesielska, Agnieszka Wanda, et al.
Publicado: (2012)

Possible Benefit of Angiotensin II Receptor Blockers in COVID-19 Patients: A Case Series
por: Lee, Su Jin, et al.
Publicado: (2021)

Angiotensin II Receptor Blockers and Arrhythmias in Ventricular Hypertrophy
por: Salama, Guy
Publicado: (2022)

Clinical Pharmacogenetics of Angiotensin II Receptor Blockers in Iraq
por: Al-Hussaniy, Hany A., et al.
Publicado: (2023)

The presence of kynurenine aminotransferases in the human cornea: Evidence from bioinformatics analysis of gene expression and immunohistochemical staining
por: Matysik-Woźniak, Anna, et al.
Publicado: (2017)

The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Moretti, Myla E., et al.
Publicado: (2012)

Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers—Relevance to COVID-19
por: Moore, Graham J., et al.
Publicado: (2021)

Summertime dosage-dependent hypersensitivity to an angiotensin II receptor blocker
por: Forsdyke, Donald R
Publicado: (2015)

HPLC Gradient Retention of Tryptophan and its Metabolites on Three Stationary Phases in Context of Lipophilicity Assessment
por: Wicha-Komsta, Katarzyna, et al.
Publicado: (2020)

Immunomodulatory Activity of the Most Commonly Used Antihypertensive Drugs—Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Bryniarski, Paweł, et al.
Publicado: (2022)

Pneumonia Risk and Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Liu, Chia-Lin, et al.
Publicado: (2013)

Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
por: Lee, Hyun Woo, et al.
Publicado: (2021)

Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
por: Holloway-Kew, Kara L., et al.
Publicado: (2022)

Molecular Interactions between Mecamylamine Enantiomers and the Transmembrane Domain of the Human α4β2 Nicotinic Receptor
por: Bondarenko, Vasyl, et al.
Publicado: (2014)

Clinical Profile of Eprosartan: A Different Angiotensin II Receptor Blocker
por: Blankestijn, P. J, et al.
Publicado: (2008)

Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation
por: Naccarelli, Gerald V, et al.
Publicado: (2009)

Angiotensin receptor blockers in heart failure after the ELITE II trial
por: Willenheimer, Ronnie
Publicado: (2000)

Angiotensin II receptor blockers induce autophagy in prostate cancer cells
por: Woo, Yunseo, et al.
Publicado: (2017)

Onset of Hyperkalemia following the Administration of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker
por: Jun, Hye-Ran, et al.
Publicado: (2021)

Differential Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on COVID-19
por: Su, Lianjiu, et al.
Publicado: (2021)

Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
por: Zhang, Chao, et al.
Publicado: (2021)

Visit-to-Visit Variability and Seasonal Variation in Blood Pressure With Single-Pill Fixed-Dose Combinations of Angiotensin II Receptor Blocker/Calcium Channel Blocker and Angiotensin II Receptor Blocker/Diuretic in Hypertensive Patients
por: Shiga, Yuhei, et al.
Publicado: (2015)

Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta‐blockers in patients hospitalized for acute heart failure
por: Carubelli, Valentina, et al.
Publicado: (2021)

Angiotensin II type 1 receptor blockers favorably affect renal angiotensin II and MAS receptor expression in patients with diabetic nephropathy
por: Ma, Ye-Ping, et al.
Publicado: (2020)

Combination therapy of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease
por: Vasavada, Nina, et al.
Publicado: (2009)

Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID‐19
por: Pan, Michael, et al.
Publicado: (2021)

Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials
por: Baumhäkel, Magnus, et al.
Publicado: (2011)

Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk
por: Farsang, Csaba
Publicado: (2011)

Severe Hyponatremia Associated with the Use of Angiotensin II Receptor Blocker/thiazide Combinations
por: Kim, Da-Rae, et al.
Publicado: (2013)

Prolonged Postoperative Vasoplegia in Pediatric Patients on Chronic Angiotensin II Blocker Treatment
por: Pandya, Nischal R., et al.
Publicado: (2018)

Intraoperative angioedema induced by angiotensin II receptor blocker: a case report
por: Alhowary, Ala”a, et al.
Publicado: (2018)

Effect of angiotensin II blockers on the prognosis of COVID-19: a toxicological view
por: Shirazi, Farshad M., et al.
Publicado: (2020)

Use of angiotensin II receptor blocker during pregnancy: A case report
por: Wei, Qiang, et al.
Publicado: (2021)

Angiotensin II, RAS Activation, and RAS Blockers in COVID-19: Unambiguous Evidence
por: Calò, Lorenzo A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_78cacthihshiv31t05ilrs4chq